A Systematic Review and Meta-Analysis of Diagnostic Accuracy of Xpert MTB/RIF and Line Probe Assays for Drug-Resistant Tuberculosis
Year: 2025
Type: review
Study designs: Systematic Review, Meta-Analysis
Abstract: Background: Timely and precise identification of drug-resistant tuberculosis (DR-TB) is crucial for directing appropriate treatment and curbing transmission. Rapid molecular assays, notably Xpert MTB/RIF and Line Probe Assays (LPAs), are extensively used to detect Mycobacterium tuberculosis complex and genetic markers of rifampicin (RIF) and isoniazid (INH) resistance. Nevertheless, diagnostic performance varies by setting, necessitating a pooled appraisal of the global evidence. Methods: We performed a systematic review and meta-analysis following PRISMA-DTA standards. Searches of PubMed, Embase, Scopus, Web of Science, and the Cochrane Library were carried out from database inception through March 2024 to identify studies comparing Xpert MTB/RIF or LPAs with a reference standard (phenotypic drug susceptibility testing or sequencing). Two reviewers independently applied QUADAS-2 to assess study quality and extracted data to populate 2×2 contingency tables. Pooled sensitivity, specificity, likelihood ratios, and diagnostic odds ratios (DORs) were estimated with a bivariate random-effects model, and HSROC curves were produced to summarize overall test performance. Results: Seventy-four studies comprising 39,184 clinical specimens met inclusion criteria. For detection of RIF resistance, Xpert MTB/RIF had pooled sensitivity and specificity of 93.1% (95% CI: 90.4-95.1) and 98.0% (95% CI: 96.2-98.9), respectively (AUC = 0.989). LPAs yielded pooled sensitivity and specificity for RIF of 89.7% (95% CI: 86.2-92.5) and 97.8% (95% CI: 95.6-98.9), and for INH of 88.9% (95% CI: 85.3-91.8) and 97.1% (95% CI: 94.8-98.5) (AUC = 0.982). Both platforms showed very high specificity and robust overall diagnostic accuracy, with little evidence of publication bias. Conclusion: Xpert MTB/RIF and LPAs both offer excellent diagnostic accuracy for detecting drug-resistant TB. Xpert is well suited for rapid, near-patient identification of rifampicin resistance, whereas LPAs provide broader resistance profiling by detecting isoniazid resistance concurrently. Adoption of both methods within national diagnostic pathways can facilitate earlier case detection, timely treatment initiation, and more effective DR-TB control.
Source: Journal of chemical health risks
Author: Kumar Arpit, Aabid Shafi Wani
Language: English
Subfield: Infectious Diseases
Field: Medicine
Domain: Health Sciences
Keywords: drug-resistant tuberculosis, Xpert MTB/RIF, line probe assay, rifampicin resistance, isoniazid resistance, Mycobacterium tuberculosis complex, diagnostic accuracy, molecular diagnosis, phenotypic drug susceptibility testing, sensitivity and specificity, likelihood ratios, diagnostic odds ratio, publication bias
Open Access status: diamond
Funder: Jaeb Center for Health Research
OpenAlex ID: W7217251077
